|
How Do c-Myc Antibodies Reveal New Mechanisms of Protein Interaction Regulating Gene Expression?
hits:39 Date:11/19/25
Recent Advances
1. How Do Protein Interactions Regulate Oncogene Expression?
Protein interactions play a pivotal role in regulating gene expression, particularly within the transcriptional networks controlling oncogenes. As a key transcription factor, the expression level and activity of c-Myc are precisely regulated by multiple mechanisms. Research shows that c-Myc's function depends not only on its own expression level but is also significantly influenced by its interactions with other regulatory proteins. In breast cancer cells, the HBXIP protein has been confirmed to specifically interact with c-Myc. This interaction likely regulates c-Myc's transcriptional activity through the formation of a protein complex.
Subcellular localization studies in MCF-7 breast cancer cells using immunofluorescence techniques revealed that HBXIP and c-Myc primarily co-localize within the nucleus. This finding provides crucial spatial evidence for a potential functional interaction between the two proteins. Their nuclear co-localization suggests they may function at the transcriptional level, jointly participating in the regulation of gene expression. This similarity in subcellular distribution lays the foundation for further in-depth investigation into their interaction mechanism.
2. How is the Direct Interaction Between HBXIP and c-Myc Validated?
To confirm the direct interaction between HBXIP and c-Myc, researchers employed multiple complementary experimental techniques. Co-immunoprecipitation results showed that when HBXIP was used as the bait protein, it specifically precipitated c-Myc protein; conversely, using c-Myc as the bait protein also precipitated HBXIP. This bidirectional verification strongly demonstrates a direct physical interaction between the two proteins.
To further confirm the direct nature of the interaction, researchers conducted GST pull-down assays. HBXIP protein fused to Glutathione S-transferase and immobilized on affinity resin specifically captured His-tagged c-Myc protein. This in vitro result excludes potential influences from other cellular co-factors and directly confirms the specific molecular binding capability between HBXIP and c-Myc. The mutual corroboration from these two experimental methods makes the conclusion of interaction highly reliable.
3. How is the Key Interaction Domain Determined?
Identifying the key domains responsible for protein interaction is crucial for understanding the molecular mechanism. Through bioinformatics analysis, researchers divided the HBXIP protein into three domain fragments: aa1-55, aa82-173, and aa56-173. Systematic evaluation of the binding capacity of these domains to c-Myc using co-immunoprecipitation showed that only the full-length HBXIP and the fragment containing the aa56-173 region could specifically bind to c-Myc.
Notably, when the leucine chain within the HBXIP protein was mutated, its binding ability to c-Myc was completely lost. This finding indicates that this leucine chain plays a key role in maintaining the structural integrity required for the protein interaction. GST pull-down assays further validated this result, as only the HBXIP protein containing the intact aa56-173 domain could effectively capture c-Myc protein. These discoveries precisely define the key interaction domain, providing a structural basis for a deeper understanding of the molecular binding mechanism.
4. How Does the Protein Complex Regulate Gene Transcriptional Activity?
To investigate the functional role of the HBXIP-c-Myc protein complex, researchers performed electrophoretic mobility shift assays (EMSA). Using a probe containing the c-Myc binding site E-box sequence, a clear band shift was observed after adding specific c-Myc antibody. When HBXIP antibody was added, a more pronounced super-shift band appeared, indicating that HBXIP participates in the c-Myc-DNA binding complex.
Luciferase reporter gene assays further revealed the functional significance of this interaction. Co-transfecting cells with c-Myc gene fused to the Gal4 DNA-binding domain and varying doses of HBXIP expression plasmid showed that HBXIP could dose-dependently enhance c-Myc's transcriptional activation capability. This finding indicates that HBXIP not only physically binds to c-Myc but also functionally enhances its transcriptional regulatory activity, thereby establishing a positive feedback regulatory loop.
5. How Do Multiple Experimental Methods Collaboratively Verify Protein Interaction?
In this study, the synergistic application of multiple experimental techniques provided multi-layered evidence for the protein interaction. Co-immunoprecipitation confirmed the interaction within the cellular environment, GST pull-down verified direct binding in vitro, and EMSA demonstrated the ability of the protein complex to interact with DNA. These methods collectively built a complete chain of evidence from different perspectives.
Each technique has unique advantages and limitations. Co-immunoprecipitation can reflect interactions under physiological conditions but might be affected by indirect interactions; GST pull-down can prove direct binding but lacks the native intracellular environment; EMSA specifically detects protein-DNA interactions. The complementary use of these techniques makes the research conclusions more comprehensive and reliable, providing a methodological paradigm for protein function studies.
6. What is the Biological Significance of This Discovery?
The elucidation of the HBXIP-c-Myc interaction mechanism holds significant importance for understanding oncogene regulatory networks. This discovery reveals a new regulatory mechanism for c-Myc, where HBXIP enhances c-Myc's transcriptional activity through direct interaction, forming a positive feedback loop. This regulatory mechanism likely plays an important role in tumorigenesis and development, particularly in maintaining the high expression state of oncogenes.
From a translational medicine perspective, this discovery provides a potential target for developing new cancer therapeutic strategies. Interventions targeting the HBXIP-c-Myc interaction interface could become a novel therapeutic approach, especially for c-Myc-driven tumors. Furthermore, the precise identification of the HBXIP aa56-173 domain provides a structural basis for designing specific inhibitors.
This research not only deepens our understanding of oncogene regulatory mechanisms but also demonstrates the power of integrating multiple technologies in protein function studies. Through systematic experimental design and rigorous technical validation, the researchers successfully uncovered a new gene regulatory mechanism, laying a solid foundation for subsequent research and clinical applications.
7. Which Companies Provide c-Myc Antibodies?
Hangzhou Start Biological Technology Co., Ltd. independently developed the "S-RMab® c-Myc Recombinant Rabbit Monoclonal Antibody" (Product Name: S-RMab® c-Myc Recombinant Rabbit mAb (SDT-R138), Catalog Number: S0B2165). This is a high-performance antibody product characterized by high specificity, excellent sensitivity, and outstanding staining consistency. Developed using the proprietary S-RMab® recombinant rabbit monoclonal antibody technology platform and rigorously validated across multiple platforms including Immunohistochemistry (IHC), Western Blot (WB), and Immunofluorescence (IF), it holds key application value in areas such as tumorigenesis mechanism research, cell proliferation regulation, and prognosis assessment.
Core Product Advantages:
High Specificity & Clear Nuclear Localization: Precisely recognizes the c-Myc protein, demonstrating exceptional nuclear-specific staining in Formalin-Fixed Paraffin-Embedded (FFPE) samples with a clear background and distinct signals, providing a reliable basis for accurate interpretation.
Excellent Staining Stability & Batch Consistency: Under stringent quality control standards, the product exhibits superior staining stability and minimal inter-batch variation, ensuring high comparability of results across different laboratories and experimental batches, providing stable assurance for clinical research and translational medicine.
Suitable for Key Application Scenarios:
| Application Area |
Specific Uses |
| Tumor Proliferation & Malignancy Assessment |
Used to assess proliferative activity and prognosis in various malignancies (e.g., Burkitt lymphoma, diffuse large B-cell lymphoma, neuroblastoma) as c-Myc is an important proto-oncoprotein. |
| Cell Cycle & Metabolic Regulation Research |
Used to study the core regulatory roles of c-Myc in cell cycle progression, ribosome biogenesis, and cellular metabolic reprogramming. |
| Stem Cell & Induced Reprogramming Research |
Used to investigate the function and expression dynamics of c-Myc during stem cell self-renewal and somatic cell reprogramming. |
| Targeted Therapy & Drug Discovery |
Serves as a key biomarker for c-Myc pathway inhibitors, used in efficacy evaluation and mechanism of action studies for preclinical drugs. |
Professional Technical Support: We provide detailed product technical documentation, including complete IHC experimental protocols, optimized antigen retrieval methods, and professional interpretation guidance, fully assisting customers in achieving breakthrough progress in cancer biology research and precision medicine.
Hangzhou Start Biological Technology Co., Ltd. is committed to providing high-quality, high-value biological reagents and solutions for global innovative pharmaceutical companies and research institutions. To learn more about the "S-RMab® c-Myc Recombinant Rabbit Monoclonal Antibody" (Catalog Number S0B2165) or to request a sample for testing, please feel free to contact us.
Product Information
| Catalog Number |
Product Name |
Product Parameters |
| S0B0383 |
S-RMab® Myc tag Recombinant Rabbit mAb (S-114-13) |
Host : Rabbit
Conjugation : Unconjugated |
| S0B6390 |
Phospho-c-Myc (Ser62) Recombinant Rabbit mAb (S-3428) |
Host : Rabbit
Conjugation : Unconjugated |
| S0B0754 |
c-Myc Recombinant Rabbit mAb (S-519-54) |
Host : Rabbit
Conjugation : Unconjugated |
| S0B2165 |
S-RMab® c-Myc Recombinant Rabbit mAb (SDT-R138) |
Host : Rabbit |
|
中文
